Intellection and Bruker AXS Sign Strategic Collaboration Agreement
News Apr 18, 2008
Under this agreement, Intellection will expand its range of products and services, directly supplying XRF (X-ray fluorescence) and XRD (X-ray diffraction) systems from Bruker AXS to its customers. This will allow both companies to develop highly competitive global sales strategies.
"Intellection's own technological credentials are impeccable, with our QEMSCAN® solutions the international market leader across the resources sector," said Intellection CEO Calvin Treacy. "Bruker's XRD and XRF technologies complement QEMSCAN® analysis, making them an excellent business fit for us."
"Intellection is able to strongly endorse Bruker's products - the Bruker XFlash® SD detector currently forms part of our QEMSCAN® solution, and has delivered outstanding performance and reliability."
"The combination of fast, accurate particle analysis and identification technology provided by Intellection with Bruker AXS' X-ray diffraction, powered by the unique and unmatched TOPAS data evaluation software, is the most powerful method available for quantitative phase analysis in the fields of minerals and mining," said Bruker AXS Executive Vice President Dr. Frank Burgaezy.
The new strategic collaboration agreement extends the range of analytical processes offered to customers in the mining and upstream oil and gas sectors, allowing Intellection to provide the comprehensive range of advanced automated mineralogy solutions available from any supplier on a global basis.
It will also see Intellection and Bruker AXS undertake joint product development projects to add value to both companies' technologies.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE